DiaMedica Therapeutics (DMAC) Net Cash Flow (2018 - 2026)

DiaMedica Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$10.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 2372.25% year-over-year to -$10.8 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 363.21% increase from a year earlier, with the FY2025 full-year figure at $12.6 million, up 931.49% from the prior year.
• Net Cash Flow slipped to -$10.8 million in Q1 2026 per DMAC's latest filing, from $12.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $12.3 million in Q4 2025 and bottomed at -$10.8 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$436000.0 (2025), against an average of $9470.6.
• Across the five-year window, Net Cash Flow soared 12206.67% in 2023 and tumbled 2372.25% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $2.0 million in 2022, then climbed by 18.09% to $2.3 million in 2023, then plunged by 147.99% to -$1.1 million in 2024, then surged by 1211.27% to $12.3 million in 2025, then plunged by 187.46% to -$10.8 million in 2026.
• Per Business Quant, the three latest DMAC Net Cash Flow figures stand at -$10.8 million (Q1 2026), $12.3 million (Q4 2025), and -$786000.0 (Q3 2025).